Pharmaceuticals, Biotechnology and Life Sciences
The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Sanofi’s…
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has nodded for extension for Dupixent, following USFDA’s approval for nasal polyposis, enabling its approval in the European Union (EU) to also include adolescents 12 to 17 years of age with moderate-to-severe AD who are candidates for systemic therapy.
DUBLIN–(BUSINESS WIRE)–The “Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027” report has been added to ResearchAndMarkets.com’s offering. The…
Food allergy has been essentially highly debatable for decades in atopicdermatitis, with some common food, including milk, egg, and soy. Thereis a lot of literature which provides evidence that common foodexacerbate atopic dermatitis.
MatriSys Bioscience got positive feedback from the FDA on its planned initiation of clinical trials for MSB-01 under a U.S. IND for MatriSys’ lead microbiome-based candidate, MSB-01, for the treatment of Atopic Dermatitis (AD).
Realm Therapeutics has submitted its first investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for PR022, as a novel treatment for atopic dermatitis (AD).